RLAY - relaytx.com Trailing Twelve Months Revenue Growth

Relay Therapeutics (RLAY) relies on stable reagent supplies through a diversified network of contractors. The year-over-year sales growth percentage for TTM on the GURU.Markets daily chart reflects revenue dynamics, where 24.00 demonstrates the current metric level. Outlook is driven by the success of RLY-2608 and liquidity, while the strategy is based on the Dynamo AI platform and a partnership with Pfizer to develop targeted therapies.
Relay Therapeutics, Inc. - analytical breakdowns and key metrics (RLAY)

The investment appeal of Relay Therapeutics (RLAY) is based on the commercialization of targeted cancer drugs, where revenue scaling rates determine the market value of assets. By analyzing comparable year-over-year sales growth over 12 months, an investor assesses the percentage change in annual turnover daily, which allows for filtering out short-term noise and identifying long-term fundamental business development trends.